Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 *2/*2 (C64T) (vol 18, pg 575, 2007)

被引：0
|
作者：
Usami, O.
Ashino, Y.
Komaki, Y.
机构：
来源：
INTERNATIONAL JOURNAL OF STD & AIDS | 2007年 / 18卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：726 / 726
页数：1
相关论文
共 50 条
  • [31] CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations
    Carr, Daniel F.
    Chaponda, Mas
    Castro, Elena M. Cornejo
    Jorgensen, Andrea L.
    Khoo, Saye
    Van Oosterhout, Joep J.
    Dandara, Collet
    Kampira, Elizabeth
    Ssali, Francis
    Munderi, Paula
    Lalloo, David G.
    Heyderman, Robert S.
    Pirmohamed, Munir
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) : 3329 - 3334
  • [32] The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes Lessons from Botswana
    Maseng, Monkgomotsi J.
    Tawe, Leabaneng
    Thami, Prisca K.
    Moyo, Sikhulile
    Kasvosve, Ishmael
    Novitsky, Vladimir
    Essex, Max
    Russo, Gianluca
    Gaseitsiwe, Simani
    Paganotti, Giacomo M.
    MEDICINE, 2022, 101 (17) : E29066
  • [33] High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study
    Yimer, G.
    Amogne, W.
    Habtewold, A.
    Makonnen, E.
    Ueda, N.
    Suda, A.
    Worku, A.
    Haefeli, W. E.
    Burhenne, J.
    Aderaye, G.
    Lindquist, L.
    Aklillu, E.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (06): : 499 - 506
  • [34] Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults
    Lin Cheng
    Yu Wang
    Xiaoyu Li
    Wei Feng
    Bangbi Weng
    Qian Yuan
    Peiyuan Xia
    Fengjun Sun
    The Pharmacogenomics Journal, 2020, 20 : 246 - 259
  • [35] Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism (vol 62, pg 1188, 2008)
    Garcia-Diaz, Ana
    Lok, Chun Bong
    Madge, Sara
    Booth, Clare
    Tyrer, Mervyn
    Bonora, Stefano
    Mahungu, Tabitha
    Owen, Andrew
    Johnson, Margaret
    Geretti, Anna Maria
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (03) : 688 - 688
  • [36] Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults
    Cheng, Lin
    Wang, Yu
    Li, Xiaoyu
    Feng, Wei
    Weng, Bangbi
    Yuan, Qian
    Xia, Peiyuan
    Sun, Fengjun
    PHARMACOGENOMICS JOURNAL, 2020, 20 (02): : 246 - 259
  • [37] CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients
    Olagunju, Adeniyi
    Siccardi, Marco
    Amara, Alieu
    Jevtovic, Djordje
    Kusic, Jovana
    Owen, Andrew
    Dragovic, Gordana
    THERAPEUTIC DRUG MONITORING, 2014, 36 (06) : 734 - 738
  • [38] Oral Cyclophosphamide Confounds the Relationship between CYP2C19 and CYP2B6 Pharmacogenetics and Cyclophosphamide-induced premature Ovarian Failure in Lupus Nephritis Patients
    Helsby, Nuala
    Goldthorpe, Michael
    Gow, Peter
    de Zoysa, Janak
    ADVANCES IN PHARMACOLOGY AND PHARMACY, 2013, 1 (01) : 1 - 8
  • [39] Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver (vol 11, pg 399, 2001)
    Long, T
    Klein, K
    Fischer, J
    Nussler, AK
    Neuhaus, P
    Hofmann, U
    Eichelbaum, M
    Schwab, M
    Zanger, UM
    PHARMACOGENETICS, 2001, 11 (07): : 643 - 643
  • [40] Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children
    M. Viljoen
    M. O. Karlsson
    T. M. Meyers
    H. Gous
    C. Dandara
    M. Rheeders
    European Journal of Clinical Pharmacology, 2012, 68 : 339 - 347
12345